Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation

PLoS One. 2014 Jul 17;9(7):e102368. doi: 10.1371/journal.pone.0102368. eCollection 2014.

Abstract

Respiratory syncytial virus (RSV) is a major cause of morbidity and mortality worldwide, causing severe respiratory illness in infants and immune compromised patients. The ciliated cells of the human airway epithelium have been considered to be the exclusive target of RSV, although recent data have suggested that basal cells, the progenitors for the conducting airway epithelium, may also become infected in vivo. Using either mechanical or chemical injury models, we have demonstrated a robust RSV infection of p63+ basal cells in air-liquid interface (ALI) cultures of human bronchial epithelial cells. In addition, proliferating basal cells in 2D culture were also susceptible to RSV infection. We therefore tested the hypothesis that RSV infection of this progenitor cell would influence the differentiation status of the airway epithelium. RSV infection of basal cells on the day of seeding (MOI≤0.0001), resulted in the formation of an epithelium that showed a profound loss of ciliated cells and gain of secretory cells as assessed by acetylated α-tubulin and MUC5AC/MUC5B immunostaining, respectively. The mechanism driving the switch in epithelial phenotype is in part driven by the induced type I and type III interferon response that we demonstrate is triggered early following RSV infection. Neutralization of this response attenuates the RSV-induced loss of ciliated cells. Together, these data show that through infection of proliferating airway basal cells, RSV has the potential to influence the cellular composition of the airway epithelium. The resulting phenotype might be expected to contribute towards both the severity of acute infection, as well as to the longer-term consequences of viral exacerbations in patients with pre-existing respiratory diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Differentiation*
  • Cell Proliferation
  • Cells, Cultured
  • Epithelial Cells / cytology*
  • Epithelial Cells / virology
  • Humans
  • Interferon Type I / immunology
  • Interferons
  • Interleukins / immunology
  • Mucin 5AC / metabolism
  • Mucin-5B / metabolism
  • Respiratory Mucosa / cytology
  • Respiratory Mucosa / virology*
  • Respiratory Syncytial Virus Infections / immunology*
  • Respiratory Syncytial Virus Infections / pathology*
  • Respiratory Syncytial Virus Infections / virology
  • Respiratory Syncytial Viruses / immunology
  • Respiratory Syncytial Viruses / pathogenicity
  • Stem Cells / virology
  • Tubulin / metabolism

Substances

  • interferon-lambda, human
  • Interferon Type I
  • Interleukins
  • MUC5AC protein, human
  • MUC5B protein, human
  • Mucin 5AC
  • Mucin-5B
  • Tubulin
  • Interferons

Grants and funding

This study was funded by Novartis Institutes for Biomedical Research. Authors B. D. Persson, A. B. Jaffe and H. Danahay are employees of Novartis Institutes for BioMedical Research. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.